evaluate the effect of a single administration of SB-509 in subjects
with mild to moderate DN.
-- Complete follow-up and presentation of data in the second half of the
year from a Phase 2 study (SB-509-601) to evaluate the effects of
SB-509 in subjects with mild to moderate DN.
-- Complete accrual, follow-up and presentation of data from a Phase 2
study (SB-509-701) to evaluate SB-509 in subjects with moderate to
-- Complete accrual and treatment in the recently initiated Phase 2
pharmacokinetic trial (SB-509-703) to evaluate the effect of SB-509 on
stem cell mobilization
-- Initiate a Phase 2 clinical trial to evaluate SB-509 for the treatment
of ALS (Amyotrophic Lateral Sclerosis, also known as "Lou Gehrig's
-- Advance ZFP Therapeutic pipeline by initiating Phase 1 clinical trials
of ZFP Therapeutics for glioblastoma and HIV / CCR5.
-- Present preclinical data in spinal cord injury, stroke, neuropathic
pain and ZFN(TM)-mediated gene modification.
Business -- Strategic Collaborations & Enabling Technology Agreements
-- Pursue strategic partnering in ZFP Therapeutics.
-- Achieve additional research milestones in Dow AgroSciences
collaboration in plant agriculture.
-- Increase visibility and value of ZFNs by developing commercial
research reagents in collaboration with Sigma-Aldrich.
-- Establish new commercial license agreements using ZFNs to improve
cell-lines used in protein production and other biological
Financials and Operations
-- Maintain year-end 2008 cash and investments balance of at least $55.0
Sangamo will host a conference call today at 5:00 p.m. ET, w
|SOURCE Sangamo BioSciences, Inc.|
Copyright©2008 PR Newswire.
All rights reserved